On May 31, 2018 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that new data from the ongoing Phase 1b clinical trial of single agent sitravatinib will be presented at the 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting to be held June 1-5, 2018 in Chicago (Press release, Mirati, MAY 31, 2018, View Source [SID1234526998]). The data will highlight initial results from the cohort evaluating sitravatinib in the treatment of patients with metastatic renal cell carcinoma (mRCC) who are refractory to anti-angiogenic therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These results demonstrate that sitravatinib is active as a single agent in the treatment of patients with refractory mRCC," said Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer. "We believe that the single agent data provide further rationale for the combination of sitravatinib with checkpoint inhibitor therapy for the treatment of mRCC. Our strategic partner, BeiGene, Ltd., intends to evaluate the combination of sitravatinib and the anti-PD-1 checkpoint inhibitor, tislelizumab, in patients with mRCC following dose and schedule confirmation, that is anticipated to begin later this year."
Title: Evaluation of the Spectrum Selective RTK Inhibitor Sitravatinib in Clear Cell Renal Cell Carcinoma (ccRCC) Refractory to Anti-Angiogenic Therapy
Presentation Date and Time: Saturday, June 2, 2018, 8:00 a.m. – 11:30 a.m. CST
Abstract Number: 4568
Poster Board: 394
Session Title: Genitourinary (Non-prostate) Cancer
Location: Hall A
About Sitravatinib
Sitravatinib is a spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. As an immuno-oncology agent, sitravatinib is being tested in combination with nivolumab (OPDIVO), an anti-PD-1 checkpoint inhibitor, in NSCLC patients who have experienced documented disease progression following treatment with a checkpoint inhibitor. Sitravatinib’s potent inhibition of TAM and split family RTKs may overcome resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment, enhancing antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation.
Sitravatinib is also being evaluated as a single agent in a Phase 1b expansion trial enrolling patients whose tumors harbor CBL, CHR4Q12 and RET genetic alterations in NSCLC and other solid tumors.